The PFS data results revealed a strongly negative prognosis for ERK1/2activation in response to the temozolomide therapy in glioblastoma and nosignificant association for the treatment of stomach cancer patients with thetargeted therapeutic ramucirumab(Fig. 7).No statistically significant difference could be observed for the ERK1/2 pathwayactivation for the RECIST responder and non-responder patient data. The gene discussed is MAPK3; the disease is gastric cancer.